Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
about
Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analysesCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis.Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies.Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies.The role of sex in uveitis and ocular inflammation.Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitisImproved survival in granulomatosis with polyangiitis: A general population-based study.Granulomatosis with polyangiitis in childhood.Myelodysplasia and malignancy-associated vasculitis.Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation.Key advances in the clinical approach to ANCA-associated vasculitis.State of the art in the treatment of systemic vasculitides.Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art.Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.The long-term outcomes of systemic vasculitis.Disease assessment in systemic vasculitis.Twenty-five years of European Union collaboration in ANCA-associated vasculitis research.Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013.Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?Cyclophosphamide in dermatology.Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.Treatment of membranous nephropathy: time for a paradigm shift.ANCA-associated vasculitis: a comparison of cases presenting to nephrology and rheumatology services.Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis.Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis.Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.The European Vasculitis Society 2016 Meeting Report.Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study.Unmet Needs in the Pathogenesis and Treatment of Vasculitides.Issues in trial design for ANCA-associated and large-vessel vasculitis.Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].Cancer risks in recipients of renal transplants: a meta-analysis of cohort studies.Granulomatosis with Polyangiitis in Children
P2860
Q24289205-D8D16DB3-78D9-41BE-81F8-F1E085F61839Q27025692-2CEBE708-C7FA-4281-B61D-AA47F556A481Q30696868-05A6B14F-28E1-44A1-8632-8386BF8F3A04Q33715801-A53B95AC-F4A1-4BE6-B622-01AB00BC3715Q34124668-B31A9D79-5D4D-4ABA-BDB3-9F75C0AA67A7Q34124711-9D0CDE92-02C5-454D-95D2-A56636803EB1Q35212086-0C47E8C9-644B-4074-91A1-17EAE0C12425Q35606909-ACD198A9-89C2-4E2D-91B6-585A7860FDC1Q35849200-67DD7447-1EAB-4C11-AE82-F1EB303547C8Q36583330-4CF43238-E54B-40C7-AF51-7D83D76AF640Q37227906-3EB89864-8FC3-4FAE-B64D-8A2732F30F9FQ37979678-98F8B29E-D87C-41F0-8EDB-5330265ED75CQ38028379-5233A636-2EC4-4326-A1D0-6ED649BBCFFFQ38082794-5BEAF454-B320-42F3-B1A2-558E480A6FD2Q38224803-9FDCA230-4FFE-41A5-84AA-D4B20BE6FFD7Q38263514-082457D6-22E2-4B5A-AC81-1E7B17D2FA8EQ38276417-CF68E0AE-CDF2-4ACF-BEAE-CEAF747F7F46Q38316279-2C731387-CB41-4851-901F-E84C8AAB70D4Q38324168-D3304DA4-AAC5-4EFE-8D1B-AD455E4C8D91Q38348251-2C505307-C757-4FD7-BC8A-E1F5DB3849E2Q38389839-FC923C81-B87E-43EF-8A2D-69DA39C8010FQ38413238-FCC5907D-8855-4529-AE16-5B5B63187B4EQ38543360-49FE7698-E5FF-4D0E-B179-4C5FAA3A1F9DQ38710150-30B982BC-4ACE-4B76-B2F4-7BFB658FB7A9Q38965278-AD3D1D26-A1DC-4747-A170-1A132BB2E588Q39410091-FC52364F-C878-4A24-A3F8-FF165FC0CC45Q39673095-518C84FD-BCE3-479E-B9EB-8637F9983E7CQ40208466-002C3219-84B9-4003-955E-9636EB2E3CB8Q41208157-46EB1ADF-F557-4229-B204-0240CD970477Q41687182-0D33E743-30A8-46BD-93D8-9C9A8083B2D7Q41733954-AE7A153A-589D-463C-9832-DDA812F4A535Q47105115-177187B5-C760-4E31-804C-DD53439BC806Q47107377-425A2853-3B76-4D37-9873-139932260CA2Q48102349-879E5CF2-4181-4FEB-AA08-7AA9B25F5FAFQ48592090-887794A6-82AA-4D3F-98F8-A407E9375925Q48937679-7CC51E04-58C6-4FD2-9DCD-E2F40F6723FBQ49595577-90A4ECD4-11FD-43F3-9C75-3FCB9839D962Q50076914-5C78B7B9-0CBD-490C-8B00-7ABEDDED49F6Q55262322-400E45AC-C03B-41A7-9A85-EE7C24B2FD97Q59160666-B95F03C6-1F57-4745-8CF6-15B46C479DF8
P2860
Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Incidence of malignancy in pat ...... s Study Group clinical trials.
@ast
Incidence of malignancy in pat ...... s Study Group clinical trials.
@en
type
label
Incidence of malignancy in pat ...... s Study Group clinical trials.
@ast
Incidence of malignancy in pat ...... s Study Group clinical trials.
@en
prefLabel
Incidence of malignancy in pat ...... s Study Group clinical trials.
@ast
Incidence of malignancy in pat ...... s Study Group clinical trials.
@en
P2093
P356
P1476
Incidence of malignancy in pat ...... s Study Group clinical trials.
@en
P2093
D G I Scott
European Vasculitis Study Group (EUVAS)
O Flossmann
P304
P356
10.1136/ARD.2010.145250
P407
P577
2011-05-25T00:00:00Z